Atacand is a brand name of candesartan, approved by the FDA in the following formulation(s):
ATACAND (candesartan cilexetil - tablet; oral)
Manufacturer: ASTRAZENECA
Approval date: June 4, 1998
Strength(s): 16MG, 32MG [RLD], 4MG, 8MG
Has a generic version of Atacand been approved?
No. There is currently no therapeutically equivalent version of Atacand available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Atacand. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-c arboxylate and compositions and methods of pharmaceutical use thereof
Patent 5,196,444
Issued: March 23, 1993
Inventor(s): Naka; Takehiko & Nishikawa; Kohei & Kato; Takeshi
Assignee(s): Takeda Chemical Industries, Ltd.
1-(Cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-car boxylate or a pharmaceutically acceptable salt thereof has potent angiotensin II antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.
Patent expiration dates:
Pharmaceutical compositions for oral use and method of preparing them
Patent 5,534,534
Issued: July 9, 1996
Inventor(s): Makino; Tadashi & Mizukami; Yashio & Kikuta; Jun-ichi
Assignee(s): Takeda Chemical Industries, Ltd.
A pharmaceutical composition for oral use comprising an effective amount of a compound of the formula (I) having antagonistic action to angiotensin II ##STR1## (wherein the ring W is an optionally substituted N-containing heterocyclic residue; R.sup.3 is a group capable of forming an anion or a group convertible thereinto; X is a direct bond or a spacer having an atomic length of two or less between the phenylene group and the phenyl group; and n is an integer of 1 or 2) and an oily substance having a lower melting point, and a method for preparing a pharmaceutical composition for oral use comprising an effective amount of a compound of the formula (I) and an oily substance having a lower melting point, which comprises admixing the compound of the formula (I) with an oily substance having a lower melting point and then subjecting the mixture to molding.
Patent expiration dates:
- July 9, 2013
✓
Drug product
- January 9, 2014
✓
Pediatric exclusivity
Benzimidazole derivatives and use thereof
Patent 5,705,517
Issued: January 6, 1998
Inventor(s): Naka; Takehiko & Nishikawa; Kohei
Assignee(s): Takeda Chemical Industries, Ltd.
Benzimidazole derivatives of the formula (I): ##STR1## wherein the ring A is a benzene ring which may optionally contain substitution in addition to the R' group; R' is hydrogen or an optionally substituted hydrocarbon residue; R.sup.2 is a group capable of forming an anion or a group convertible thereinto; X is a direct bond or a spacer having an atomic length of two or less between the phenylene group and the phenyl group; R' is carboxyl, an ester thereof, an amide thereof or a group capable of forming an anion or convertible to an anion; Y is --O--, --S(O).sub.m -- or --N(R.sup.4)-- wherein m is an integer of 0, 1 or 2 and R.sup.4 is hydrogen or an optionally substituted alkyl group; and n is an integer of 1 or 2; and the pharmaceutically acceptable salts thereof, have potent angiotensin II antagonistic activity and antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.
Patent expiration dates:
- October 18, 2011
✓
Pediatric exclusivity
Benzimidazole derivatives, their production and use
Patent 7,538,133
Issued: May 26, 2009
Inventor(s): Naka; Takehiko & Nishikawa; Kohei & Kato; Takeshi
Assignee(s): Takeda Pharmaceutical Company Limited
Benzimidazole derivatives of the formula (I): wherein the ring A is a benzene ring which may optionally contain substitution in addition to the R′ group; R1 is hydrogen or an optionally substituted hydrocarbon residue; R2 is a group capable of forming an anion or a group convertible thereinto; X is a direct bond or a spacer having an atomic length of two or less between the phenylene group and the phenyl group; R′ is carboxyl, an ester thereof, an amide thereof or a group capable of forming an anion or convertible to an anion; Y is —O—, —S(O)m— or —N(R4)— wherein m is an integer of 0, 1 or 2 and R4 is hydrogen or an optionally substituted alkyl group; and n is an integer of 1 or 2; and the pharmaceutically acceptable salts thereof, have potent angiotensin II antagonistic activity and antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.
Patent expiration dates:
- October 18, 2011
✓
Pediatric exclusivity
See also...
- Atacand Consumer Information (Drugs.com)
- Atacand Consumer Information (Wolters Kluwer)
- Atacand Consumer Information (Cerner Multum)
- Atacand Advanced Consumer Information (Micromedex)
- Atacand AHFS DI Monographs (ASHP)
- Candesartan Consumer Information (Wolters Kluwer)
- Candesartan Consumer Information (Cerner Multum)
- Candesartan Advanced Consumer Information (Micromedex)
- Candesartan cilexetil Advanced Consumer Information (Micromedex)
- Candesartan Cilexetil AHFS DI Monographs (ASHP)
